Our onco-metabolism approach brings
an enhanced perspective to cancer.
- Company
- Therapeutic Areas
- Programs
- Clinical Trials
- Investors
- Financial Information
- Corporate Governance
- Shareholder Services
-
Calithera Biosciences to Present Telaglenastat KEAPSAKE Trial in Progress Poster at the IASLC 2021 World Conference on Lung Cancer
-
Calithera Biosciences to Participate in Two Upcoming Investor Conferences
-
Calithera Biosciences Reports Second Quarter 2021 Financial Results and Recent Highlights
-
Calithera Biosciences to Report Second Quarter 2021 Financial Results on Thursday, August 5, 2021
-
Final Data from Calithera Biosciences’ Phase 2 CANTATA Study in Renal Cell Carcinoma Presented at 2021 ASCO Annual Meeting
Development Pipeline
Calithera is a clinical-stage biopharmaceutical company pioneering the discovery and development of targeted, small molecule therapies that disrupt cellular metabolic pathways to preferentially block tumor cell growth and enhance immune-cell activity.
Recent News
- Shareholder Services
- Corporate Governance
- Financial Information
- Investors
- Clinical Trials
- Programs
- Therapeutic Areas
